Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
AssigneesYeda Research & Development Co. Ltd. of Weizmann Institute of Science, ImmunoBrain Checkpoint, Inc.
InventorsMichal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising an active agent that causes reduction of the loved of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
Claims25
1-23. (canceled)
A method of treating an Alzheimer's Disease, the method comprising administering to an individual in need thereof a composition comprising an antibody against an immune checkpoint molecule,
- wherein:
- the composition is administered by a dosage regime comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session where the composition is administered to the individual followed by a non-treatment period where the composition is not administered to the individual,
- the non-treatment period is longer than the treatment session;
- and,
- if administration of the composition during the treatment session is a repeated administration, the non-treatment period is longer than the period between repeated administrations during the treatment session.
Dependencies are inferred from the claim text.